Causa Prima Raises $10.0M Pre-Seed Round

BrainFocus

BrainFocus is a medtech start-up based in Barcelona that works with clinicians to help them improve care for patients suffering from epilepsy. We develop unique computational tools to assist epileptologists in the diagnosis and treatment of drug-resistant epilepsy, specialising in intracranial EEG. The company, which is a spin-off from Universitat Politècnica de Catalunya (UPC), was founded by Adrià Tauste Campo, Manel Vila-Vidal and Bart Huisken in Ferbruary 2023. With more than 15 years of research experience at the BrainFocus research lab, our team is determined to bring cutting-edge advances in computational neuroscience to real epilepsy care. Our first product is BrainFocus iEEG, a cloud-based software that improves and speeds up the diagnostic process with a variety of quantitative and visualisation tools, highlighting seizure patterns that remain invisible to the human eye. Our solution assists clinicians during diagnosis, reducing the error associated with visual inspection and increasing the diagnostic accuracy.

Flavii Therapeutics

Flavii Therapeutics S.L. is a biotechnology company focused on developing epigenetic therapies for central nervous system (CNS) disorders. We are committed to transforming lives by offering new hope to patients and families affected by these conditions, which currently lack curative treatment options. Our lead program, FLAV-27, is a first-in-class small molecule that acts as a potent and selective inhibitor of G9a, a key epigenetic regulator involved in brain function. FLAV-27 is a SAM-competitive inhibitor, offering high specificity with minimal off-target effects. It demonstrates excellent blood-brain barrier penetration and favorable pharmacokinetic/pharmacodynamic (PK/PD) properties. Preclinical studies have shown that FLAV-27 provides neuroprotection and improves neuroinflammation and neuronal plasticity in models of Alzheimer’s disease, Huntington’s disease, and neurodevelopmental disorders. It enhances cognition, memory, motor function, and social behaviors. Toxicology studies confirm a strong safety profile, with no adverse effects observed even at doses 200 times higher than the therapeutic dose. Flavii is advancing FLAV-27 towards clinical trials, aiming to deliver a novel, disease-modifying treatment that addresses the root causes of CNS disorders and offers real hope to patients.